Resources Library
Pivotal Phase III trial undergoes audits by the FDA and sponsor
Challenge: A pivotal Phase III clinical trial of C1 inhibitor for the prophylactic treatment of hereditary angioedema managed by ARG […]
June 1, 2018
ARG Strategic Advisory Board Meeting 5/24
The ARG SAB (Strategic Advisory Board) regularly convenes to discuss emerging trends and issues in rare diseases, adding to the […]
May 24, 2018
CEO Paul Bishop and President Lyle Camblos on "Are There Too Many CROs?"
Each quarter, ARG CEO Paul Bishop and President Lyle Camblos will share their thoughts and responses concerning relevant company and […]
May 22, 2018
ARG Presence at Alliance For Regenerative Medicine Annual Dinner & Legislative Fly-In
Jeff Cazeault, Head of Business Development at ARG, is in Washington, DC to attend the Alliance for Regenerative Medicine Annual […]
May 22, 2018
Project Manager Katherine Pryor Test Drives Kanban
Earlier this year we introduced ARG’s use of Kanban as an organizational model–and tool, as many team members employed a […]
May 15, 2018
Does Your CRO Innovate To Keep Trials On Track?
ARG knows from experience that the willingness to be flexible has fueled our success in rare disease clinical trials, resulting in approvals with over $3B in sales.
May 9, 2018